| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|
Phase N/A 1
2 3 4 Trials | | 0 | 13263952657891104117130 |
|---|
| | | | |
|---|
| | | | |
|---|
| | | | |
|---|
| Ixempra (ixabepilone) / Otsuka, R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Kanarb (fimasartan) / Boryung Group, R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Deltyba (delamanid) / Otsuka | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Brexafemme (ibrexafungerp) / SCYNEXIS, GSK | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Artlegia (olokizumab) / R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Taigexyn (nemonoxacin) / TaiGen | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Arcerix (goflikicept) / R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Careram (iguratimod) / Eisai, R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Arlansa (narlaprevir) / Merck (MSD) | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Ituxredi (rituximab biosimilar) / Dr. Reddy’s, Abbott, EMD Serono, CinnaGen, Fresenius Kabi, R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| Supect (radotinib) / IL-Yang Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| nonavalent HPV vaccine / Beijing Health Guard Biotech, R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| RPH-001 (bevacizumab biosimilar) / R-Pharm, Alphamab | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| alofanib (RPT835) / R-Pharm | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
| cefilavancin (TD-1792) / Theravance Biopharma | | | |
|---|
| | |
|---|
| | |
|---|
| | | | |
|---|
| | | | |
|---|
|
